Key Highlights

  • Revenue was USD 98.29 million against an estimate of USD 100.52 million and USD 83.33 million last year.
  • Net loss per share was USD 0.46 against an estimated USD 0.39 loss and a USD 0.38 loss last year.
  • Handpieces and other consumables Revenue was USD 60.8 million, against USD 49.7 million a year earlier.
  • Cash was USD 218.4 million at quarter end, and USD 52.0 million is outstanding on its term loan.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reported third quarter revenue of USD 98.29 million against an estimate of USD 100.52 million and USD 83.33 million in the same quarter of 2025. The surgical robotics company, whose AquaBeam and HYDROS systems deliver Aquablation therapy for benign prostatic hyperplasia, posted a net loss of USD 26.5 million, or USD 0.46 per share, against an estimated loss of USD 0.39 per share.

Results and Headline Figures

The company stated that revenue increased 18% in the quarter and 19% for the nine months, to USD 275.9 million from USD 231.7 million. It attributed the growth to higher sales volumes of systems, handpieces, other consumables and service contracts, with USD 85.8 million of third quarter revenue from the United States.

Gross profit was USD 65.1 million against USD 54.0 million, and gross Margin was 66% against 65%. Management linked the year-over-year margin increase mainly to Tariff refunds of USD 3.2 million. Loss from operations was USD 27.4 million against USD 23.2 million, and net loss was USD 26.5 million against USD 21.4 million. The net loss per share of USD 0.46 compares with USD 0.38 a year earlier.

Revenue Lines and Operating Expenses

System sales and leases were USD 29.2 million against USD 28.1 million, an increase the company stated as 4%. Handpieces and other consumables were USD 60.8 million against USD 49.7 million, up 22%, and service revenue was USD 8.3 million against USD 5.5 million, up 51%.

Research and development expense was USD 20.0 million against USD 18.2 million. Selling, general and administrative expense was USD 72.5 million against USD 59.0 million.

As of September 30, 2026, the install base was 1,095 robotic systems globally, including 858 in the United States. The company said it has created a dedicated team to upgrade existing AquaBeam systems to HYDROS and reorganized its Aquablation representatives to focus on system utilization.

Cash, Debt and Legal Matters

Cash and cash equivalents were USD 218.4 million, and the accumulated Deficit was USD 726.6 million. For the nine months, net cash used in Operating Activities was USD 66.4 million against USD 38.7 million, and the net loss was USD 85.0 million against USD 65.7 million.

The senior secured term Loan Facility with Canadian Imperial Bank of Commerce carries USD 52.0 million of principal. In September 2026, a third amendment extended the Maturity by 12 months to October 1, 2028.

The company also disclosed that a putative securities class action was filed on July 24, 2026 and a Shareholder derivative action on September 15, 2026, both in the U.S. District Court for the Northern District of California. Both are at an early stage, and the company said it cannot predict the outcome or estimate any loss.

Figures Worth Comparing

Revenue of USD 98.29 million sits alongside a gross margin of 66%, an operating loss of USD 27.4 million and cash of USD 218.4 million.

The company provided no numeric guidance. Management named growing the install base of HYDROS systems, raising system utilization, reimbursement and coverage decisions, and continued research and development, including work on artificial intelligence and Machine Learning for treatment planning, as the factors that shape its performance. It stated that expenses continue to rise with its Investment in sales, operations and research.